|1.||Ryan, Donna H: 9 articles (12/2014 - 08/2003)|
|2.||Hendricks, Ed J: 8 articles (04/2015 - 09/2009)|
|3.||Day, Wesley W: 6 articles (06/2014 - 04/2011)|
|4.||Rothman, Richard B: 5 articles (04/2015 - 09/2009)|
|5.||Garvey, W Timothy: 5 articles (12/2014 - 02/2012)|
|6.||Bray, George A: 5 articles (08/2014 - 08/2003)|
|7.||Gadde, Kishore M: 5 articles (03/2014 - 04/2011)|
|8.||Aronne, Louis J: 4 articles (04/2015 - 09/2010)|
|9.||Troupin, Barbara: 4 articles (12/2014 - 04/2011)|
|10.||Proietto, Joseph: 3 articles (08/2014 - 01/2005)|
|1.||Weight Loss (Weight Reduction)
01/01/1983 - "The results showed that there was a significantly greater weight loss in patients treated with phentermine which was particularly marked during the last 4 weeks of the study. "
09/01/2013 - "The mean weight loss was 3.8 ± 4.0 kg. AEs are commonly associated with phentermine, even though phentermine is effective for weight loss and relatively well-tolerated."
10/31/2006 - "The aim of this study is to verify the effect of phentermine on weight reduction and the safety in Korean patients. "
04/01/2000 - "A partial crossover design was used to study a weight loss treatment consisting of Phentermine hydrochloride (Fastin, SmithKline Beecham Pharmaceuticals, Philadelphia, PA) therapy plus a low energy diet (5040 kJ/d). "
01/01/2016 - "These results suggest that individuals reporting greater hunger and less restraint are more likely to achieve significant weight loss with phentermine. "
09/01/2012 - "Phentermine is widely used in many countries despite its multiple adverse effects and lack of proven efficacy in preventing complications of obesity."
04/01/1974 - "A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity."
09/01/2013 - "Postmarketing surveillance study of the efficacy and safety of phentermine in patients with obesity."
10/01/2010 - "Further study is needed to show long-term efficacy and safety of phentermine DCR in Korean patients with obesity."
12/01/2009 - "There remains a need for more studies of phentermine to better define its place in obesity management."
|3.||Body Weight (Weight, Body)
10/31/2006 - "Mean decrease of both body weight and waist circumference in phentermine-treated subjects were significantly greater than that of placebo group (weight: -6.7 +/- 2.5 kg, p < 0.001; waist circumference: -6.2 +/- 3.5 cm, p < 0.001). "
10/01/2010 - "The participants in the phentermine DCR group showed significant reductions in body weight (-8.1 ± 3.9 vs. -1.7 ± 2.9 kg, p < 0.001) and waist circumference (7.2 ± 0.5 vs. 2.1 ± 0.6 cm, p < 0.001) compared with those in the placebo group. "
01/01/1982 - "No signs of toxicity, as evidenced by the maintenance of body weight, or lethality were observed in the neonates of the phentermine-treated dams."
01/01/1979 - "(A significant difference among the mean percentage body weight reduction for the three behavioral groups was also found.) In addition, a group of 'slow losers' who initially lost less than one half-pound (0.2 kg) per week and were subsequently placed on phentermine lost significantly more weight than a similar group which continued on placebo. "
06/01/1985 - "Self-administration of phentermine by naive rats: effects of body weight and a food delivery schedule."
02/01/2014 - "To investigate if phentermine treatment induces phentermine abuse, psychological dependence (addiction) or phentermine drug craving in overweight, obese and weight loss maintenance patients. "
06/01/2014 - "Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk. "
01/01/2014 - "The combination agent phentermine/topiramate ER has been shown to reduce weight in overweight and obese subjects in a number of studies. "
09/01/2013 - "This review describes the pharmacology and clinical trials data for phentermine/topiramate ER and its role in a complications-centric approach to medical care of the overweight and obese patient. "
04/16/2011 - "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial."
|5.||Cocaine-Related Disorders (Cocaine Addiction)
04/14/1997 - "These results suggest that phentermine, as well as its combination with fenfluramine, may be useful in the treatment of cocaine abuse."
07/01/1997 - "Combination of the dopaminergic agent, phentermine, and the serotonergic agent, fenfluramine, in the treatment of cocaine dependence."
12/20/1996 - "Coadministration of phentermine and fenfluramine has been used to treat cocaine dependence. "
02/01/1999 - "These results show that phentermine is effective in decreasing cocaine self-administration and suggest that it may be an effective medication for cocaine abuse."
03/01/2001 - "The dopamine reuptake inhibitor GBR 12909 and the dopamine releaser phentermine may have potential for the treatment of cocaine abuse in humans. "
|3.||8- chloro- 2,3,4,5- tetrahydro- 1- methyl- 1H- 3- benzazepine
|2.||Self Administration (Administration, Self)
|3.||Drug Therapy (Chemotherapy)